PeptideStack
5.2kquestions
20kanswers
220users

How comparable are retatrutide and mazdutide on the evidence available?

Asked 24 Jul 2026Modified 6 days agoViewed 308 times
1

Setup, so nobody has to ask: retatrutide · mazdutide.

Both of these get recommended confidently by different people, which suggests neither is obviously right.

My constraints are cost, measurement resolution and how much handling I am prepared to do — in roughly that order.

Under what conditions does the answer flip?

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

162 questions
shareeditfollowflag
NK
askednadia_kowalczyk14k1724 Jul 2026

No answers yet

This question has not been answered. It has been viewed 308 times, which suggests the question is of interest and the answer is not obvious. If you can answer it with a source or a worked calculation, it will be read. See how to ask and answer.
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.